Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZMapp in Ebola Virus Infection (PREVAIL II)
NCT02363322Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2015
- Primary completion
- Dec 2017
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of ZMapp in Ebola virus disease (EVD), sponsored by National Institute of Allergy and Infectious Diseases. Started Mar 2015; status: completed.
02
Drugs
ZMapp
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT02363322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02363322.